Callado L F, Stamford J A
Academic Department of Anaesthesia and Intensive Care, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Royal London Hospital, Whitechapel, UK.
Eur J Pharmacol. 1999 Jan 29;366(1):35-9. doi: 10.1016/s0014-2999(98)00889-9.
In this study, we used subtype-selective antagonists to determine the subtype of alpha2-adrenoceptor controlling noradrenaline release in rat locus coeruleus. Noradrenaline release was measured in locus coeruleus slices using fast cyclic voltammetry at carbon fibre microelectrodes. On long stimulation trains (40 pulses, 20 Hz), the alpha2A-adrenoceptor selective antagonist BRL 44408 (2-[2H-(1-methyl-1,3-dihydroisoindole) methyl]-4,5-dihydroimidazole) at 100 nM and 1 microM significantly increased stimulated noradrenaline release, whereas the alpha2B/C-selective antagonist ARC 239 (2-[2[4-(o-methoxyphenyl)piperazin-1-yl] ethyl]-4,4dimethyl-1,3-(2H,4H)-isoquinolinedione) at 50 and 500 nM had no effect. On short stimuli (20 pulses, 200 Hz), the non-specific alpha2-adrenoceptor agonist dexmedetomidine (10 nM) significantly decreased noradrenaline release, an effect reversed by BRL 44408 (1 microM) but not by ARC 239 (500 nM). These data demonstrate that autoreceptor control of noradrenaline release in the locus coeruleus is mediated by alpha2A but not alpha2B/C-adrenoceptors.
在本研究中,我们使用亚型选择性拮抗剂来确定控制大鼠蓝斑中去甲肾上腺素释放的α2 - 肾上腺素能受体亚型。使用碳纤维微电极上的快速循环伏安法测量蓝斑切片中的去甲肾上腺素释放。在长刺激序列(40个脉冲,20Hz)下,100nM和1μM的α2A - 肾上腺素能受体选择性拮抗剂BRL 44408(2 - [2H - (1 - 甲基 - 1,3 - 二氢异吲哚)甲基] - 4,5 - 二氢咪唑)显著增加刺激的去甲肾上腺素释放,而50和500nM的α2B/C - 选择性拮抗剂ARC 239(2 - [2[4 - (邻甲氧基苯基)哌嗪 - 1 - 基]乙基] - 4,4 - 二甲基 - 1,3 - (2H,4H) - 异喹啉二酮)没有作用。在短刺激(20个脉冲,200Hz)下,非特异性α2 - 肾上腺素能受体激动剂右美托咪定(10nM)显著降低去甲肾上腺素释放,该作用被BRL 44408(1μM)逆转,但不被ARC 239(500nM)逆转。这些数据表明,蓝斑中去甲肾上腺素释放的自身受体控制是由α2A而非α2B/C - 肾上腺素能受体介导的。